Piper Sandler raised the firm’s price target on Cigna (CI) to $374 from $348 and keeps an Overweight rating on the shares. The firm notes Cigna reported a Q1 adjusted EPS beat led by Cigna Healthcare, where premium growth reflects continued momentum in the Select employer segment, second half of 2025 Stop Loss renewals were executed on plan, and reported MLR of 82.2% that was 80 bps better than forecast. The 2025 revised guidance looks conservative, in Piper’s view.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target raised to $390 from $379 at Morgan Stanley
- Cigna price target raised to $407 from $395 at BofA
- Cigna’s Strategic Innovations and Financial Resilience Justify Buy Rating
- Cigna price target raised to $382 from $339 at Barclays
- Cigna’s Strong Q1 Performance and Growth in Specialty Segments Drive Buy Rating